Drug combinations used for the treatment of non-small-cell lung cancer (NSCLC) and melanoma aren’t as effective as they could be. That could change with a new algorithm developed by a cross-disciplinary Vanderbilt University team for calculating drug synergy.
News: February, 2019
The American Heart Association (AHA) has issued a scientific statement calling for the integration of cardio-oncology and vascular medicine to provide cancer patients and cancer survivors with optimal cardiovascular care.
Researchers have discovered that a new “checkpoint” protein on immune system cells is active in tumors, and that blocking it — in combination with other treatments — is a successful therapeutic approach in mouse models of cancer.
Changes in enzymes involved in lysophospholipid signaling can activate a pathway implicated in development of cancer, a recent study suggests.
A new study improves the understanding of how the stomach-dwelling bacterium Helicobacter pylori influences the risk of premalignant and malignant changes in the stomach.
Breast cancer patients who message their doctors about certain topics are more likely to discontinue hormone therapy than others, enabling doctors to better predict which patients are at risk of stopping their treatment early.
Vanderbilt University Medical Center will host an educational symposium on human papillomavirus (HPV) and associated cancers on Friday, March 1.
Daniel Barocas, MD, MPH, associate professor of Urology, is being recognized with a national award from the Society of Urologic Oncology (SUO) for his efforts to develop urologic cancer quality measures.
A Vanderbilt initiative to develop predictive imaging technologies that clinicians can use to better match patients with personalized care has received National Cancer Institute (NCI) funding.
Vanderbilt researchers have linked a specific form of programmed cell death to myelodysplastic syndrome, a type of bone marrow failure.